



**PRO****ORE PHARMA**  
leading-edge medical innovation

# Promore Pharma AB Year-End Financial Report

Solna, Feb 2021

# Promore Pharma in Brief

- Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market
- Two first-in-category human therapeutic peptides for local administration – addressing a USD 7-8 billion market with high growth
- The two product candidates have extraordinary safety profile
- Cost effective organization without in-house laboratories or research facilities
- The company is listed on Nasdaq First North since July 2017



**Vision**      **To solve the global problems of scarring, adhesions and chronic wounds**

2020

THE PAST OPERATING YEAR

# Achievement Highlights

## R&D PROGRAMS

- Manufacturing process development for ensereptide
- Preparations for the PHSU03 trial
- Patent granted for ropocamtide in the US
- Data from the HEAL LL-37 trial concluded


## BUSINESS & TEAM

- Launch of a long-term incentive program
- Erik Magnusson appointed CFO
- Erik Penser Bank assigned as Certified Advisor
- Initiation of a strategic re-alignment

**Completion of HEAL LL-37 represent the single largest accomplishment**

# Q4 2020 Financials

## Operating expenses



Cash development	Q1'20	Q2'20	Q3'20	Q4'20
Net cash flow	-14,7	-5,9	-8,6	-7,1
Cash position	45,9	39,9	31,3	24,2


- Decreased costs in Q4 as HEAL comes to an end
  - Operating expenses SEK 4m lower yoy both in the quarter and for the FY
  - Primarily lower clinical trial related costs
  - Corporate costs slightly lower
  - Some HEAL costs yet in Q1
  
- Net cash flow in Q4 was SEK -7.1m
  - SEK -36.3m accumulated
  
- Cash position of SEK 24.2m by the end of December 2020

**Costs lower than prior year, and in line with the stage of the HEAL LL-37 program**


# Efficacy in Patients with Large Wounds ( $\geq 10 \text{ cm}^2$ )

## Per Protocol Analysis Set


**Frequency of Complete Closure (%)**



**Frequency of 70% Closure (%)**



**Wound Healing Rate (day<sup>-1</sup>)**




ROP LD = ropocamptide 0.5 mg/ml

ROP HD = ropocamptide 1.6 mg/ml

**There is a clear-cut medical benefit of ropocamptide in large VLUs**

# Wound Size and Treatment Costs

**An average VLU  
is ~6-7 cm<sup>2</sup>**



- Patients having VLUs larger than 10 cm<sup>2</sup> and having a wound duration of >6 months have a weekly treatment cost 3x per week\* compared to small ulcers with short duration
- Given the longer treatment time required, large wounds account for an estimated 60%-90% of the VLU market opportunity
- Ropocamptide may be uniquely positioned to address an important market segment


\*Ebbeskog, B. Et al. (1996) Scand J Prim Health Care 14: 238-243



# Enhancement of the Ensureptide Supply Chain



# Ensereptide is a Versatile Product Candidate



**Ensereptide presents a strong potential for expansion of indications**

# Strategic Planning



## **Ongoing strategic analysis of main options for Promore Pharma, involving an assessment of:**

- A detailed analysis of the path forward for the ropocamptide program: next steps, costs, possibilities for partnerships
- An updated assessment of costs and timelines in various ensereptide initiatives
- Long-term effects of the COVID-19 pandemic, in particular as it relates to conduct of clinical trials in various areas
- Assessment of opportunities for strategic partnering in the company's main programs
- The ability for the company to perform value-enhancing initiatives in light of the current financial situation

**External communication aimed for March/April**

# Concluding Remarks

**Portfolio with solutions for multiple medical conditions with unmet needs in advanced wound care**



**THANK YOU!**

# Important Notice & Disclaimer

THIS PRESENTATION AND ANY OTHER INFORMATION DISCUSSED AT THE PRESENTATION (THE "PRESENTATION") IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION, WHICH HAS BEEN PREPARED AND IS ISSUED BY PROMORE PHARMA AB (THE "ISSUER") IS PRELIMINARY IN NATURE, BASED ON MANAGEMENT BELIEFS AND IS SUBJECT TO UPDATING, REVISION AND AMENDMENT. THIS PRESENTATION MAY NOT BE REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF APPLICABLE SECURITIES LAWS.

This Presentation does not, and is not intended to, constitute or form part of, and should not be construed as, (i) any offer, solicitation or invitation to subscribe for, sell or issue, underwrite or otherwise acquire any shares, securities or financial instruments of the Issuer or its parent (the "Securities"), nor shall it, or the fact of its communication, form the basis of or be relied upon in connection with or act as any inducement to enter into any contract or commitment whatsoever with respect to any Securities; or (ii) any form of financial opinion, recommendation or investment advice with respect to any Securities. This Presentation is not a prospectus. Any decision to purchase Securities in the context of an offering should be made on the basis of information contained in the offering circular expected to be published by the Issuer in due course in relation to such an offering. The information and opinions contained in this Presentation are provided as at the date of the Presentation, are subject to change without notice and do not purport to contain all information that may be required to evaluate the Issuer. The information in this presentation is in draft form and has not been independently verified. Neither the Issuer, nor Redeye AB ("Financial adviser") or any of their respective partners, directors, officers, advisers, affiliates or representatives undertake or is under any duty to update this Presentation or to correct any inaccuracies in any such information which may become apparent or to provide you with any additional information. None of the foregoing persons accept any responsibility whatsoever for the contents of this Presentation and no representation or warranty, express or implied, is made by any such person in relation to the contents of this Presentation, and no reliance should be placed on, fairness, accuracy or completeness of the information and opinions contained in this Presentation. The Issuer and the Financial adviser and their respective directors, officers, employees, partners, advisers and agents expressly disclaim, to the maximum extent permitted by law, any and all liability, whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in connection with the accuracy or completeness of the information or for any of the opinions contained herein, or any other written or oral information made available in connection with this Presentation, or for any errors, omissions or misstatements contained in this Presentation or such other information. None of the Issuer and Financial adviser or any of their respective directors, officers, employees, partners, advisers and agents shall have any liability whatsoever (in negligence or otherwise) for any direct, indirect or consequential loss, damages, costs or prejudices whatsoever arising from the use of this Presentation or its contents or otherwise arising in connection with this Presentation. The information contained in the Presentation does not constitute and may not be relied on in any manner as legal, tax, investment, accounting, regulatory or other advice on, about or in relation to the Issuer, nor does it constitute a recommendation regarding the Securities. You should seek independent and professional advice and conduct your own independent investigation and analysis of the information contained in this Presentation and of the business, operations, financial condition, prospects, status and affairs of the Issuer. This Presentation contains various forward-looking statements that reflect the Issuer's management's current views with respect to future events and anticipated financial and operational performance and include, among other things, changing economic, business or other market conditions, changing regulatory conditions and the prospects for growth. Forward-looking statements as a general matter are all statements other than statements as to historical facts or present facts or circumstances. The words "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions, identify certain of these forward-looking statements. Other forward-looking statements can be identified in the context in which the statements are made. Although Promore Pharma AB believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements. All statements (including forward looking statements) contained herein are made as of the date of this Presentation. The Issuer expressly undertakes no obligation to update or revise this Presentation in case such estimates, projections or forward-looking statements do not materialize or change in the future and the parties named above disclaim any such obligation to do so. Accordingly, prospective investors are cautioned not to place undue reliance on any of the forward-looking statements herein. Certain market and competitive position data contained in this Presentation has been obtained from published and non-published industry publications or reports conducted by third parties. Such publications or reports generally state that the information they contain has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed. Neither the Issuer nor the Financial adviser have verified and can give no assurances as to the accuracy of such information, market data or other information contained in this Presentation that was extracted or derived from these publications and reports. Certain statements in this Presentation regarding the market and competitive position data are based on the internal analyses of the Issuer, which may involve certain assumptions and estimates based on the knowledge and experience of its management. Although the Issuer believes that its internal observations are reliable, its estimates are not reviewed or verified by any external sources. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this Presentation. The Securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, delivered, distributed or transferred, directly or indirectly, into or within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Issuer does not intend to make any public offering of Securities in the United States. This presentation and its contents may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose. In the United Kingdom, this Presentation is directed only at persons who are "Qualified Investors" within the meaning of meaning of Article 2(1)(e) of Directive 2003/71/EC, as amended (the "Prospectus Directive") (i) who have professional experience in matters relating to investments who fall within the definition of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); and/or (ii) fall within Article 49(2)(a) to (d) of the Order ("high net worth companies, unincorporated associations etc."); and/or (iii) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). In other member states of the European Economic Area, this Presentation is directed only at Qualified Investors. Any investment or investment activity to which this Presentation may relate would, if made available and engaged in, be made available only to and engaged in only with such persons. This Presentation must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the European Economic Area other than the United Kingdom, by persons who are not Qualified Investors. By attending a meeting where this Presentation is made, or by otherwise accessing the Presentation, you warrant, represent, undertake and acknowledge that: (i) you have read and agree to comply with the foregoing limitations and restrictions, (ii) you are able to receive this Presentation without contravention of any applicable legal and regulatory restrictions and you understand the sanctions attached to the misuse, disclosure or improper circulation of the Presentation, (iii) if you are in the European Economic Area, you are a Qualified Investor, and (iv) if you are in the United Kingdom, you are a Relevant Person.